Daniel P. McLaughlin

Decreased hippocampal expression of a glutamate receptor gene in schizophrenia

A striking and specific loss of the messenger RNA that encodes a non-N-methyl D-aspartate (non-NMDA) glutamate receptor was found in hippocampal tissue obtained at necropsy from 6 patients with schizophrenia, when compared to specimens from 8 controls without neurological or psychiatric signs or symptoms. These findings support suggestions of aberrant glutamatergic function in schizophrenia. Evidence that gene expression may be abnormal in schizophrenia, with decreased production of an excitatory neurotransmitter receptor, may have therapeutic as well as pathogenetic implications.

Control of dorsal raphé 5-HT function by multiple 5-HT1 autoreceptors: parallel purposes or pointless plurality?

The serotonergic cells of the dorsal raphé nucleus innervate much of the forebrain and are thought to be involved in the mechanism of action of antidepressants. Dysfunction of these cells might be involved in the neural mechanisms underlying depression and suicide. The traffic in pathways emanating from the dorsal raphé nucleus is controlled by 5-HT(1) autoreceptors. Until recently it was thought that the autoreceptors in the dorsal raphé nucleus were solely of the 5-HT(1A) subtype. In this article, we discuss evidence that the situation is more complex and that multiple 5-HT(1) subtypes govern different aspects of 5-HT function in the dorsal raphé nucleus presenting new therapeutic opportunities.

Stereoselective effects of ketamine on dopamine, serotonin and noradrenaline release and uptake in rat brain slices.

Ketamine (2-(2-chlorophenyl)-(1-methylamino)-cyclohexanone) is a rapid-acting dissociative general anaesthetic whose hallucinogenic properties have made it a popular drug of abuse. Ketamine comprises two optical isomers, with differing pharmacology. In the present study, the effects of (+)- and (-)-ketamine on stimulated efflux and reuptake of dopamine (DA), noradrenaline (NA) and serotonin (5-HT) were compared in isolated superfused slices of the rat caudatoputamen (CPu), ventral bed nucleus of the stria terminalis (BSTV) or dorsal raphe nucleus (DRN), respectively. Monoamine efflux was elicited by local electrical stimulation (20 pulses, 100 Hz trains) at tungsten microelectrodes and measured at adjacent carbon fibre microelectrodes using fast cyclic voltammetry (FCV). In CPu (+)-ketamine increased stimulated DA efflux and slowed DA reuptake in a concentration-dependent manner (25-200 microM). At 100 microM (+)-ketamine increased DA efflux by 109+/-20% (mean+/-S.E.M., n=13) of control values after 30 min (P<0.001 versus control) and prolonged uptake half-time (t(1/2)) by 76+/-38% (n=9, P<0.001) of control. In contrast (-)-ketamine (100 microM) had no effect on DA efflux or uptake. In DRN, both isomers (100 microM) increased stimulated 5-HT efflux. (-)-Ketamine had a larger effect (P<0.001), an 88+/-15% increase in 5-HT efflux (n=9) versus 46+/-10% (n=8) for the (+)-isomer. The isomers had similar effects on 5-HT uptake, increasing t(1/2) by approximately 200%. No evidence of stereospecificity was seen in BSTV: both isomers had small effects (+)- and (-)-ketamine (100 microM) increasing NA efflux by 43+/-10% (n=7, P<0.001) and 29+/-8% (n=7, P<0.001), respectively. The isomers also had identical effects on NA uptake, each increasing uptake t(1/2) by approximately 100%. In summary, our data show that the optical isomers of ketamine have strikingly different stereospecificity for the monoamine systems and one might predict, therefore, a different psychotomimetic potential.

Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function

The atypical analgesic tramadol has strong structural similarities to the antidepressant venlafaxine and is a mixed noradrenaline (NA) and serotonin (5-HT) uptake inhibitor. Because tramadol has been found active in the forced swim test, a common predictor of antidepressant efficacy, we therefore examined the effects of chronic tramadol on various pre- and post-synaptic monoamine measures. Male Wistar rats (150–200 g) received tramadol (20 mg/kg i.p.) or vehicle for 21 days and were sacrificed 24 h after the last dose. Quantitative autoradiography revealed that specific frontocortical [3H]dihydroalprenolol and [3H]ketanserin binding was lower in the chronic tramadol group than controls (β: 37 ± 8 and 217 ± 56 fmol/mg; 5-HT2A: 23 ± 3 and 44 ± 7 fmol/mg, respectively, p < 0.05). Chronic tramadol had no effect on the magnitude of electrically stimulated noradrenaline (NA) efflux or uptake in locus coeruleus (LC) slices. Although dexmedetomidine (10 nM) decreased LC NA efflux equally (by approximately 60%) in chronic tramadol and vehicle groups, desipramine (50 nM) increased LC NA efflux more in vehicle (to 164 ± 7%) than tramadol-treated rats (144 ± 6%; p< 0.05). Chronic tramadol had no effect on dorsal raphé (DRN) or median raphé (MRN) 5-HT efflux. However, 5-HT uptake in tramadol-treated rats was slower (p < 0.05) in MRN and nearly so (p= 0.055) in DRN. The selective 5-HT1A agonist 8-OH-DPAT reduced 5-HT efflux in both DRN and MRN. Its effect in DRN was greater in rats given chronic tramadol than in vehicle controls (54 ± 2 versus 32 ± 6% reduction in 5-HT efflux, respectively). In conclusion, we suggest that tramadol has many of the pre and postsynaptic neurochemical features of a conventional antidepressant, as might be predicted from its pharmacology.

Expression of serotonin transporter mRNA in human brainstem raphe nuclei

The distribution of the messenger RNA (mRNA) encoding the serotonin transporter was investigated in the entire extent of the ascending raphe systems of the human brainstem, using a sensitive cRNA probe. This mRNA is abundant in the neurons of the raphe nuclei, especially in the dorsal and median raphe. The subregional distribution of this mRNA closely corresponds to that described for tryptophan hydroxylase in immunocytochemical studies. It is expressed at the highest levels in ventral and ventrolateral subregions of the dorsal raphe, with lower levels of expression in the median raphe, oral pontine reticular nuclei, and the supralemniscal cell groups. These results provide a description of the distribution of this mRNA in normal subjects and will serve as the basis for future studies of the subregional distribution of this mRNA in the brains of depressed patients and those who have committed suicide.

Altered presynaptic function in monoaminergic neurons of monoamine oxidase-A knockout mice

Monoamine oxidase‐A knockout (MAO‐A KO) mice have elevated brain serotonin (5‐HT) and noradrenaline (NA) levels, and one would therefore anticipate increased monoamine release and compensatory changes in other aspects of presynaptic monoamine function. In this study we used voltammetry in brain slices from the locus coeruleus (LC), dorsal raphe (DRN) and striatum (CPu) in 7‐week‐old MAO‐A KO and C3H control mice to measure stimulated monoamine efflux and its control by amine transporters and autoreceptors. In LC, peak NA efflux on stimulation (99 pulses, 100 Hz) was higher in MAO‐A KO than C3H mice (938 ± 58 nm cf. 511 ± 42 nm; P < 0.001). The NA uptake half time (t½) was longer in MAO‐A KO than in C3H mice (6.0 ± 0.9 s cf. 1.9 ± 0.3 s; P < 0.001) and the selective NA reuptake inhibitor desipramine (50 nm) had a smaller effect in MAO‐A KO mice. NA transporter binding was significantly lower in the LC of MAO‐A KO mice compared to C3H controls (P < 0.01) but not in the DRN. The α2 agonist dexmedetomidine (10 nm) decreased stimulated NA efflux more in C3H than in MAO‐A KO mice (73.3% cf. 29.6% inhibition, P < 0.001). In DRN, peak 5‐HT efflux on stimulation (99 pulses, 100 Hz) was greater (P < 0.01) in MAO‐A KO (262 ± 44 nm) than C3H mice (157 ± 16 nm). Moreover, 5‐HT uptake t½ was longer (P < 0.05) in MAO‐A KO than in C3H mice (8.8 ± 1.1 s cf. 4.9 ± 0.6 s, P < 0.05) and the effect of citalopram (75 nm) was attenuated in MAO‐A KOs. Serotonin transporter binding was also lower in both the DRN and LC of MAO‐A KO mice. The 5‐HT1A agonist 8‐OH‐DPAT (1 µm) decreased 5‐HT efflux more in C3H than in MAO‐A KO mice (38.3% inhibition cf. 21.6%, P < 0.001). In contrast, there were no significant differences between MAO‐A KO and C3H mice in CPu dopamine efflux and uptake and the effect of the D2/3 agonist quinpirole was similar in the two strains. In summary, MAO‐A KO mice show major dysregulation of monoaminergic presynaptic mechanisms such as autoreceptor control and transporter kinetics.

Adrenoceptors mediating relaxation to catecholamines in rat isolated jejunum.

1 The characteristics of adrenoceptors mediating relaxation to catecholamines in rat isolated jejunum were investigated. 2 Catecholamines and BRL 37344 produced relaxation of the KCl‐contracted strips with an order of potency of isoprenaline (1.0) > BRL 37344 (0.63) > noradrenaline (0.1) > adrenaline (0.04). 3 In the presence of both prazosin (1 μm) and propranolol (1 μm) only small dextral shifts of the concentration‐response curves to agonists were observed and an order of potency of BRL 37344 (2.5) > isoprenaline (1.0) > noradrenaline (0.2) > adrenaline (0.1) was obtained. 4 In the presence of prazosin (1 μm) and propranolol (1 μm), cyanopindolol (0.1 − 10 μm) produced a concentration‐dependent rightward shift of the concentration‐response curve to adrenaline with a Schild slope not significantly different from unity and a mean pA2 value of 7.01. 5 The resistance of relaxant responses to propranolol, the relatively high potency of BRL 37344 compared to catecholamines and the competitive antagonism of relaxant responses to adrenaline by cyanopindolol suggest that β‐adrenoceptors in rat small intestine are mainly atypical in nature.

Different α2 adrenoceptor subtypes control noradrenaline release and cell firing in the locus coeruleus of wildtype and monoamine oxidase‐A knockout mice

In this study, we investigated which subtype(s) of α2‐adrenoceptor control stimulated noradrenaline (NA) release and noradrenergic cell firing in the locus coeruleus (LC) of monoamine oxidase‐A knockout (MAO‐A KO) and C3H/HeJ wildtype mice. On short stimulus trains (10 pulses, 200 Hz), the α2 agonist dexmedetomidine (10 nm) reduced NA efflux by 78 ± 8% and 51 ± 8% in wildtype and MAO‐A KO mice, respectively. In both strains, BRL 44408 (100 nm) and ARC 239 (100 nm) each partially blocked the effect of dexmedetomidine. In MAO‐A KO mice, BRL 44408 (100 nm) increased evoked NA efflux on short trains while ARC 239 (100 nm) had no effect. The two antagonists in combination increased NA efflux (by 81 ± 34%, P < 0.001), significantly more than by BRL 44408 alone. Conversely, in wildtype mice, the α2‐adrenoceptor antagonists did not significantly increase LC NA efflux. On long stimuli (30 pulses, 10 Hz), NA efflux was increased by BRL 44408 (P < 0.001) but not by ARC 239. The effect of BRL 44408 was significantly greater in MAO‐A KO than wildtype mice (208 ± 43% vs. 113 ± 31% increase, P < 0.001). When we examined noradrenergic cell firing, we found that dexmedetomidine inhibited LC cell firing in both strains with comparable EC50 values (2–5 nm), although Emax was significantly lower in MAO‐A KO mice (P < 0.001). The agonist effect was antagonized by BRL 44408 (P < 0.001) in wildtype but not in MAO‐A KO mice, with a pKB of 7.75. ARC 239 had no effect on the agonist response in either strain. A combination of the antagonists was no more effective than BRL 44408 alone (in wildtypes) and had no effect in MAO‐A KO mice. Neither BRL 44408 nor ARC 239 affected basal LC cell firing in wildtype or MAO‐A KO mice. Collectively, these results suggest that, analogous to other monoamine cell groups, there are differences in the autoreceptor populations controlling NA efflux and LC cell firing and that important differences exist between MAO‐A KO and wildtype mice

Comparison of ketamine stereoisomers on tissue metabolic activity in an in vitro model of global cerebral ischaemia

Ketamine (2-o-chlorophenenyl-2-methylaminocyclohexanone hydrochloride) is a dissociative general anaesthetic with neuroprotective properties. Since ketamine is optically active, we compared the neuroprotective efficacy of the (+)- or (-)-enantiomers in global cerebral ischaemia. Rat corticostriatal slices superfused with, or incubated in, artificial CSF at 34 degrees C were subjected to a brief ischaemic insult. Dopamine efflux was measured using fast cyclic voltammetry. Tissue metabolism was determined with 2,3,5-triphenyltetrazolium chloride staining, a marker of mitochondrial enzyme activity. In control slices, ischaemia caused rapid striatal dopamine release (to 122 microM over 18 s) after an initial delay of 149s. Racemic ketamine (100 micromol/l) significantly delayed (by 24%, P<0.05), slowed (by 63%, P<0.01) and reduced (by 27%, P<0.05) ischaemia-induced dopamine release. Ischaemia (10 min) also caused significant decreases in striatal (25%, P<0.01) and cortical (31%, P<0.001) metabolic activity, manifested as a drop in mean TTC staining intensity. Racemic ketamine and its (+)- and (-)-enantiomers (each 100 microM) attenuated the loss of metabolic activity in the striatum. However, in the cortex, only (+)-ketamine (100 microM) was significantly neuroprotective. We conclude that neuroprotection by ketamine in cerebral ischaemia is both region- and isomer-dependent.

LY393615, a novel neuronal Ca2+ and Na+ channel blocker with neuroprotective effects in models of in vitro and in vivo cerebral ischemia

In the present studies we have examined the effects of a new calcium channel blocker, LY393615 ((N-Butyl-[5,5-bis-(4-fluorophenyl)tetrahydrofuran-2-yl]methylamine hydrochloride, NCC1048) in a model of hypoxia-hypoglycaemia in vitro and in a gerbil model of global and in two rat models of focal cerebral ischaemia in vivo. Results indicated that LY393615 protected against hypoxia-hypoglycaemic insults in brain slices and also provided significant protection against ischaemia-induced hippocampal damage in gerbil global cerebral ischaemia when dosed at 10, 12.5 (P<0.05) or 15 mg/kg i.p. (P<0.01) 30 min before and 2 h 30 min after occlusion. The compound penetrated the brain well after a 15 mg/kg i.p. dose and had a half-life of 2.5 h. In further studies LY393615 was protective 1 h post-occlusion when administered at 15 mg/kg i.p. followed by 2 doses of 5 mg/kg i.p. 2 and 3 h later. LY393615 dosed at 15 mg/kg i.p. followed by 2 further doses of 5 mg/kg i.p. (2 and 3 h later) also produced a significant reduction in the infarct volume following Endothelin-1 (Et-1) middle cerebral artery occlusion in the rat when administration was initiated immediately (P<0.01) or 1 h (P<0.05) after occlusion. The compound was also evaluated in the intraluminal monofilament model of focal ischaemia. The animals had the middle cerebral artery occluded for 2 h, and 15 min after reperfusion LY393615 was administered at 15 mg/kg i.p. followed by 2 mg/kg/h i.v. infusion for 6 h. There was no reduction in infarct volume using this dosing protocol. In conclusion, in the present studies we have reported that a novel calcium channel blocker, LY393615, with good bioavailability protects against neuronal damage caused by hypoxia-hypoglycaemia in vitro and both global and focal cerebral ischaemia in vivo. The compound is neuroprotective when administered post-occlusion and may therefore be a useful anti-ischaemic agent.